News Boehringer buys immunotherapy biotech AMAL Therapeutics Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and vaccines in oncology.
News Boehringer and Sarah Cannon team for immune-oncology venture Partnership will seek to develop two immune checkpoint inhibitor candidates.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face